Monomethyl fumarate

Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3].

Product Specifications

CAS Number

[2756-87-8]

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Drug Metabolite; GPR109A

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/monomethyl-fumarate.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(OC)/C=C/C(O)=O

Molecular Formula

C5H6O4

Molecular Weight

130.10

Precautions

H302, H315, H319, H335

References & Citations

[1]Tang H, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008 Oct 31;375 (4) :562-5.|[2]Jiang D, et al. Monomethyl Fumarate Protects the Retina From Light-Induced Retinopathy. Invest Ophthalmol Vis Sci. 2019 Mar 1;60 (4) :1275-1285.|[3]Sghaier R, et al. Dimethyl fumarate and monomethyl fumarate attenuate oxidative stress and mitochondrialalterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7β-hydroxycholesterol. J Steroid Biochem Mol Biol. 2019 Nov;194:105432.